AstraZeneca and Clovis Oncology have submitted their next-generation EGFR kinase inhibitors for regulatory review.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
16 November 2015
The text was revised to clarify that the first published report of a T790M EGFR inhibitor came from Nathanael Gray's lab.
Rights and permissions
About this article
Cite this article
Mullard, A. Cancer drug developers counteract kinase gatekeeper mutations. Nat Rev Drug Discov 14, 667–668 (2015). https://doi.org/10.1038/nrd4742
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4742
This article is cited by
-
Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy
Amino Acids (2020)
-
Erratum: Cancer drug developers counteract kinase gatekeeper mutations
Nature Reviews Drug Discovery (2015)
